Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease - Yahoo Finance

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta Topline results demonstrated a favorable tolerability and immunogenicity… [+21120 chars]

full article...